TITLE

Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania

AUTHOR(S)
Tarimo, Edith A. M.; Thorson, Anna; Kohi, Thecla W.; Mwami, Joachim; Bakari, Muhammad; Sandström, Eric; Kulane, Asli
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10 Issue 1, p292
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Results from HIV vaccine trials on potential volunteers will contribute to global efforts to develop an HIV vaccine. The purpose of this study among police officers in Dar es Salaam, Tanzania, was to explore the underlying reasons that induce people to enrol in an HIV vaccine trial. Methods: We conducted discussions with eight focus groups, containing a total of 66 police officers. The information collected was analyzed using interpretive description. Results: The results showed that participants were motivated to participate in the trial by altruism, and that the participants experienced some concerns about their participation. They stated that altruism in the fight against HIV infection was the main reason for enrolling in the trial. However, young participants were seriously concerned about a possible loss of close relationships if they enrolled in the HIV vaccine trial. Both men and women feared the effect of the trial on their reproductive biology, and they feared interference with pregnancy norms. They were unsure about risks such as the risks of acquiring HIV infection and of suffering physical harm, and they were unsure of the intentions of the researchers conducting the trial. Further, enrolling in the trial required medical examination, and this led some participants to fear that unknown diseases would be revealed. Other participants, however, saw an opportunity to obtain free health services. Conclusions: We have shown that specific fears are important concerns when recruiting volunteers to an HIV vaccine trial. More knowledge is needed to determine participants' views and to ensure that they understand the conduct of the trial and the reasons it is being carried out.
ACCESSION #
52038911

 

Related Articles

  • Initiative for HIV vaccine research funded - Quest for a shot persists.  // Contraceptive Technology Update;Dec2012 STI Quarterly, p1 

    The article reports on a 2012 decision which the National Institute of Allergy and Infectious Diseases made to award $31 million to Duke University in Durham, North Carolina and the Scripps Research Institute in La Jolla, California as leaders of the new Centers for HIV/AIDS Vaccine Immunology &...

  • Understanding Antibody Functions: Beyond Neutralization. von Bubnoff, Andreas; Kresge, Kristen Jill // VAX;Jan2010, Vol. 8 Issue 1, p4 

    The article reports on the effort of the medical research community to develop new HIV vaccines that are capable of inducing neutralizing antibodies. A study conducted by the researchers in Thailand indicates that prime-boost regimen can reduce the risk of HIV infection by about 30% as compared...

  • U.S. HIV vaccine trial halts shots: What is the next step in research?  // Contraceptive Technology Update;Jul2013 STI Quarterly, p1 

    The article reports on a 2013 decision which the U.S.National Institute of Allergy and Infectious Diseases made to halt the administration of injections in its clinical trial of an investigational HIV vaccine regimen after data indicated that it did not prevent HIV infection or reduce viral load...

  • BECAUSE IT'S THERE. Koretz, Ronald L. // American Journal of Gastroenterology;Dec1993, Vol. 88 Issue 12, p1991 

    Introduces an article about research on HIV infections published in the December 1993 issue of the "American Journal of Gastroenterology."

  • Quick recovery?  // Echo Magazine;1/13/2005, Vol. 16 Issue 9, p54 

    Reports on a vaccine that strengthen the body's immune system against the autoimmune aftereffects of HIV infection, developed by researchers from Hadassah University Medical Center in Jerusalem as of January 2005. Effect of the vaccine on the continuation of autoimmune process; Statistics of...

  • A Shot of Prevention. Berkley, Seth // Foreign Policy;May/Jun2007, Issue 160, p48 

    The author suggests that development of an AIDS vaccine is possible and necessary to the prevention of the disease. 25 million people have succumbed to the disease, with 4.3 million contracting HIV last year alone. There are more than 30 trials underway in 24 countries for a vaccine. Clinical...

  • A New Adenovirus Based Vaccine Vector Expressing an Eimeria tenella Derived TLR Agonist Improves Cellular Immune Responses to an Antigenic Target. Appledorn, Daniel M.; Aldhamen, Yasser A.; DePas, William; Seregin, Sergey S.; Liu, Chyong-Jy J.; Schuldt, Nathan; Quach, Darin; Quiroga, Dionisia; Godbehere, Sarah; Zlatkin, Igor; Sungjin Kim; McCormick, J. Justin; Amalfitano, Andrea // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular immune responses, but these responses failed to prevent HIV...

  • Recent Advances in Humanized Mice: Accelerating the Development of an HIV Vaccine. Tager, Andrew M.; Pensiero, Michael; Allen, Todd M. // Journal of Infectious Diseases;Nov2013 Supplement 2, Vol. 208 Issue suppl 2, pS121 

    Recent advances in the development of humanized mice hold great promise to advance our understanding of protective immunity to human immunodeficiency virus (HIV) infection and to aid in the design of an effective HIV vaccine. This supplement of the Journal of Infectious Diseases summarizes work...

  • New Antiviral Strategy Has Potential Role In HIV Prophylaxis. Kingman, Sharon // BioWorld Today;11/12/2013, Vol. 24 Issue 218, p1 

    The article focuses on the development of an antiviral strategy which seeks to solve the mystery of HIV cell infection. A study was conducted by a team of researchers led by molecular virology professor Greg Towers where they manipulated the interaction between the virus and the host cell to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics